Psilocybin for Major Depressive Disorder

"This study is looking for 30 individuals aged 18-65 who have unipolar depression. Candidates must meet the following conditions: Currently experiencing a major depressive episode without any psychotic features that has lasted for at least 3 months;, A diagnosis of major depressive disorder or bipolar II disorder from a healthcare professional;, Failed to respond to two different guideline-concordant pharmacological treatments for the current MDE, as determined by the Massachusetts General Hospital-Antidepressant Treatment History Questionnaire;, Be able to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and comply with all study visits., No history of"

"Psilocybin's safety is estimated to be a 2. This is because Phase 2 trials, of which this is one, support the substance's safety but not its efficacy."

"At the moment, 37 clinical trials are researching Psilocybin with none of them in Phase 3. Most of these studies taking place in Vancouver and Washington but there are 40 locations total running these sorts of investigations."

"As of now, this trial has finished recruiting patients. The study was posted on November 19th 2021 and last edited on March 2nd 2022. For those looking for similar studies, there are 1360 trials for unipolar depression and 37 trials concerning Psilocybin that are still admitting participants."

"The age range for this particular study is 18 to 65 years old. Out of the 1341 total clinical trials, 205 are for patients younger than eighteen while 1036 are geared towards an older crowd."

"According to the listing on clinicaltrials.gov, this trial is not currently recruiting patients for participation. The study was initially posted on November 19th, 2021 but was most recently updated on March 2nd, 2022. Although this particular trial has closed recruitment, there are 1,397 other trials that are still enrolling patients."